Ripple Secures Licenses in Singapore and Europe for Institutional Products

Ripple is securing additional licenses in Singapore and Europe to expand utility-driven institutional products, according to a report from Tokenpost citing Ripple's official newsroom. The licensing push is aimed at positioning the company for regulated cross-border use cases in markets where institutional counterparties require clear compliance frameworks. This development is characterized as a utility and infrastructure initiative, separate from ongoing litigation with the U.S. Securities and Exchange Commission.

Ripple Secures Licenses in Singapore and Europe for Institutional Products

Ripple is obtaining additional regulatory licenses in Singapore and Europe, according to Tokenpost, which cited Ripple's official press releases. The stated objective is to expand utility-driven institutional products. The company is working to position itself for regulated cross-border use cases, particularly in jurisdictions where institutional counterparties require established compliance infrastructure. The licensing activity is described as focused on utility and infrastructure rather than being tied to courtroom developments in the United States.

FAQ

What licenses is Ripple securing?
Ripple is securing additional licenses in Singapore and Europe, according to Tokenpost citing Ripple's official newsroom. The report does not specify the exact license types or regulatory bodies involved.

Why is Ripple expanding its licensing footprint?
Ripple stated the purpose is to expand utility-driven institutional products and position itself for regulated cross-border use cases in markets where institutional counterparties need clear compliance frameworks, according to the Tokenpost report citing Ripple's press releases.

Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments